<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034255</url>
  </required_header>
  <id_info>
    <org_study_id>INGAP-01-001</org_study_id>
    <nct_id>NCT00034255</nct_id>
  </id_info>
  <brief_title>Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients</brief_title>
  <official_title>Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GMP Endotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GMP Endotherapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single and multiple
      doses of intramuscular INGAP Peptide given for the first time in humans as a potential
      treatment for diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>62</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INGAP Peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients meeting all of the following inclusion criteria at screening can be considered for
        admission to the study.

        Stage 1 and Stage 2:

          1. Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years
             of age, or type 2 diabetes mellitus that are 30 through 70 years of age.

          2. Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes
             mellitus, and are currently well managed with insulin, with or without metformin.

          3. Patients who have been on stable doses of insulin treatment for 90 days prior to study
             randomization.

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria at screening will not be enrolled
        in the study:

          1. Patients with a history of any clinically significant retinopathy, symptomatic
             autonomic neuropathy, unstable angina, or kidney problems.

          2. Patients with an uncontrolled or untreated significant pulmonary, neurological
             condition, or cardiovascular disease, including hypertension, congestive heart
             failure, angina, or peripheral vascular disease.

          3. Patients who have received any investigational product within 30 days of admission
             into the study.

          4. Patients with a history or clinical evidence of multiple organ autoimmune disorders.

          5. Patients with a medical condition, serious intercurrent illness, or extenuating
             circumstance that would significantly decrease study compliance, including all
             prescribed follow-up.

          6. Patients who are lactating and breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VASDHS Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Research Institute - Clinical Research Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Diabetes, Endocrinology, Metabolism Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2002</study_first_submitted>
  <study_first_submitted_qc>April 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

